ZYTIGA® (abiraterone acetate)
ZYTIGA - COU-AA-302 Study

SUMMARY

A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:

- ZYTIGA® (abiraterone acetate) - COU-AA-302 Study
  - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below



Note: AE, adverse event; BID, twice daily; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; IA1, first interim analysis; mCRPC, metastatic castration-resistant prostate cancer; NR, not reached; OS, overall survival; PO, orally; PSA, prostate-specific antigen; QD, once daily; R, randomization; rPFS, radiographic progression-free survival; TTPP, time to PSA progression.